Table 1. Structures and Selected Data of Topical JAK Inhibitors in Clinical Trials in Atopic Dermatitis.
| tofacitiniba | delgocitinibb | ruxolitinibb | CEE321c | |
|---|---|---|---|---|
| cellular potencyd INFa (JAK1/TYK2) | 68 | 42 | 65 | 85 |
| whole blood potencyd IL2 (JAK1/3) | 30 | 30 | 329 | 2349 |
| Clinte | <25 | <25 | 40 | 166 |
Phase 2.
Approved.
Phase 1.
IC50 [nM], assay protocols in the Supporting Information.
Intrinsic clearance in human liver microsomes [μL/min mg].
